Study of inhibition of B16F10 melanoma growth in mice by landomycin A in comparison to doxorubicin
Landomycin A is a new antibiotic of angucycline group with antineoplastic activity against tumor cells of different origin. In this work, we investigated the effects of landomycin A on the growth of B16F10 mouse melanoma. It was elucidated that studied antibiotic possessed a significant dose-depende...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Львівський національний університет імені Івана Франка
2016-03-01
|
| Series: | Біологічні студії |
| Subjects: | |
| Online Access: | http://publications.lnu.edu.ua/journals/index.php/biology/article/view/62 |
| Summary: | Landomycin A is a new antibiotic of angucycline group with antineoplastic activity against tumor cells of different origin. In this work, we investigated the effects of landomycin A on the growth of B16F10 mouse melanoma. It was elucidated that studied antibiotic possessed a significant dose-dependent cytotoxic activity against these melanoma cells in vitro, and its LC50 = 2 µM was 5 times lower than that of the doxorubicin, anticancer drug widely used for treatment of solid tumors. Landomycin A at concentration of 10 mg/kg body weight did not cause pathological changes, mortality or general toxic symptoms in intact mice of C57black/6 line. No significant changes in the body weight and hematological parameters of animals treated with landomycin A as compared to the control group were observed. While B16F10 melanoma maintained rapid growth in vivo with a continual increase in tumor volume, landomycin A effectively inhibited tumor growth without a marked myelosuppressive effects or cardio- and hepatotoxicity that are characteristic for doxorubicin action. These results suggest a perspective of landomycin A application in chemotherapy of malignant tumors. |
|---|---|
| ISSN: | 1996-4536 2311-0783 |